Taltobulin (HTI-286) is a potent tubulin inhibitor.

HTI-286 significantly inhibited the proliferation of all three hepatic tumor cell lines (mean IC50: 2 nmol/L) in vitro. No decrease in viable primary human hepatocytes (PHH) was detected under HTI-286 exposure [1]. In all cell lines tested, HTI-286 was a potent inhibitor of proliferation and induced marked increases in apoptosis [2].

Intravenous administration of HTI-286 significantly inhibited tumor growth in vivo (rat allograft model) [1]. HTI-286 significantly inhibited the growth of PC-3 and LNCaP xenografts and retained potency in PC-3dR tumors. Simultaneous castration plus HTI-286 therapy was superior to sequential treatment in the LNCaP model [2].

228266-40-8

C27H43N3O4

473.65

SPA-110;HTI-286

DMSO:95 mg/mL (200.57 mM)
Powder: -20°C for 3 years
In solvent: -80°C for 2 years